Antibodies are key to helping the body’s immune system protect against disease-causing pathogens. Our bodies usually make our own antibodies but many people, including the elderly, very young children, and those who have other immune-related diseases, may have limited immunity or a compromised immune system.
Antibodies againt Ebola
As the threat of massive casualties rose at the height of the Ebola outbreak in 2014, Medicago committed to using Medicago’s technology and production platform to potentially increase the number of doses of antibodies against the Ebola virus.
- The company received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs). Two of the three mAbs were discovered by the Public Health Agency of Canada.
- Medicago produced the anti-Ebola antibodies at the company’s pilot plant in Quebec City, Canada. The production of anti-Ebola antibodies did not involve any manipulation of the virus within the company’s facilities.
- Preliminary results indicate that Medicago’s technology can rapidly produce anti-Ebola antibodies with high yields, thereby potentially boosting production volumes and worldwide supply.
As governments around the world continue to face health threats like pandemic strains of influenza and Ebola viruses, we believe that Medicago can make a major contribution to rapid response, surge capacity and stockpiles across the globe. - Andy Sheldon, Medicago CEO